Clinical Trial: Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease

U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07840027) titled 'Assessment of the Safety, Immunogenicity, and Pharmacodynamics of TRB-001 in Patients With Early Idiopathic Parkinson's Disease' on Sept. 09.

Brief Summary: This is a randomized, placebo-controlled, double-blind, dose-finding phase 1b study with the purpose to assess the safety, immunogenicity and pharmacodynamics of TRB-001 in early idiopathic Parkinson's Disease patients.

Study Start Date: Sept., 2026

Study Type: INTERVENTIONAL

Condition: Parkinson Disease (PD) Idiopathic Parkinson's Disease

Intervention: BIOLOGICAL: TRB-001

solution for intradermal injection

OTHER: Placebo

solution for intradermal injection

Recruitment...